These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Low doses of aprotinin in aortocoronary bypass surgery--advantages and disadvantages. Golański R; Golański J; Chizyński K; Iwaszkiewicz A; Zasłonka J; Pietrucha T; Chrul S; Watała C Med Sci Monit; 2000; 6(4):722-8. PubMed ID: 11208399 [TBL] [Abstract][Full Text] [Related]
27. Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin treated cardiac surgical patients undergoing cardiopulmonary bypass. Spannagl M; Dooijewaard G; Dietrich W; Kluft C Thromb Haemost; 1995 May; 73(5):825-8. PubMed ID: 7482410 [TBL] [Abstract][Full Text] [Related]
28. Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations. Liu B; Tengborn L; Larson G; Rådberg LO; Belboul A; Dernevik L; Roberts D Ann Thorac Surg; 1995 Jun; 59(6):1534-40. PubMed ID: 7539609 [TBL] [Abstract][Full Text] [Related]
29. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. Ray MJ; Marsh NA Thromb Haemost; 1997 Sep; 78(3):1021-6. PubMed ID: 9308747 [TBL] [Abstract][Full Text] [Related]
30. Aprotinin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty--a prospective randomized double-blind placebo-controlled study. Ray M; Hatcher S; Whitehouse SL; Crawford S; Crawford R J Thromb Haemost; 2005 Jul; 3(7):1421-7. PubMed ID: 15978098 [TBL] [Abstract][Full Text] [Related]
31. Tissue-type plasminogen activator and fibrin monomers synergistically cause platelet dysfunction during retransfusion of shed blood after cardiopulmonary bypass. de Haan J; Schönberger J; Haan J; van Oeveren W; Eijgelaar A J Thorac Cardiovasc Surg; 1993 Dec; 106(6):1017-23. PubMed ID: 8246533 [TBL] [Abstract][Full Text] [Related]
32. Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass. Ray MJ; Marsh NA; Just SJ; Perrin EJ; O'Brien MF; Hawson GA Ann Thorac Surg; 1997 Jan; 63(1):57-63. PubMed ID: 8993241 [TBL] [Abstract][Full Text] [Related]
33. Aprotinin improves hemostasis after cardiopulmonary bypass better than single-donor platelet concentrate. Shinfeld A; Zippel D; Lavee J; Lusky A; Shinar E; Savion N; Mohr R Ann Thorac Surg; 1995 Apr; 59(4):872-6. PubMed ID: 7535040 [TBL] [Abstract][Full Text] [Related]
34. Fibrinolytic activity during orthotopic liver transplantation with and without aprotinin. Segal HC; Hunt BJ; Cottam S; Downing A; Beard C; Francis JL; Potter D; Tan KC Transplantation; 1994 Dec; 58(12):1356-60. PubMed ID: 7528949 [TBL] [Abstract][Full Text] [Related]
35. A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor. Bovill EG; Ershler WB; Golden EA; Tindle BH; Edson JR Am J Clin Pathol; 1986 Jan; 85(1):115-23. PubMed ID: 3079626 [TBL] [Abstract][Full Text] [Related]
36. Suppressed fibrinolysis after administration of low-dose aprotinin: reduced level of plasmin-alpha2-plasmin inhibitor complexes and postoperative blood loss. Mastroroberto P; Chello M; Zofrea S; Marchese AR Eur J Cardiothorac Surg; 1995; 9(3):143-5. PubMed ID: 7540397 [TBL] [Abstract][Full Text] [Related]
37. Mini-dose pump-prime aprotinin inhibited enhanced fibrinolytic activity and reduced blood loss and transfusion requirements after coronary artery bypass surgery. Kunt AS; Darcin OT; Aydin S; Demir D; Selli C; Andac MH J Thromb Thrombolysis; 2005 Jun; 19(3):197-200. PubMed ID: 16082607 [TBL] [Abstract][Full Text] [Related]
38. [Reduction of per- and postoperative blood loss with aprotinin (Trasylol) during extracorporeal circulation]. Deleuze P; Loisance DY; Feliz A; Hillion ML; Castanié JB; Richemond J; Cachera JP Arch Mal Coeur Vaiss; 1991 Dec; 84(12):1797-802. PubMed ID: 1724365 [TBL] [Abstract][Full Text] [Related]